- Copper (II) bromide catalysed one pot bromination and amination for the green, cost-effective synthesis of clopidogrel
-
Copper (II) bromide catalyzed one pot α-bromination and followed by amination of a benzylic ester is reported. The α-bromination of ester by copper (II) bromide generates copper (I) bromide and HBr. The copper (I) bromide is oxidized to copper (II) bromide by N-Methylmorpholine-N-Oxide (NMO) in presence of HBr. The amines undergo nucleophilic substitution reaction with α-brominated ester compound. This methodology was applied for the synthesis of the familiar antiplatelet drug clopidogrel. This green process is an alternate to classical methods for the synthesis of clopidogrel, which requires, generates stochiometric amount of brominating agents and HBr, respectively.
- Kumar, K. Naveen,Mhate, Mouzma,Panchami, Hirave,Ravichandiran, V.,Swain, Sharada Prasanna
-
-
- Synthetic method of racemic clopidogrel
-
The invention relates to a synthesis method of racemic clopidogrel, which comprises the following steps: 1) uniformly mixing methyl benzoylformate, N-chlorosuccinimide, palladium acetate, a ligand andtrifluoroacetic acid, and carrying out ortho-chlorinati
- -
-
Paragraph 0031; 0035; 0040-0043; 0046
(2020/09/12)
-
- Electrolysis promoted reductive amination of electron-deficient aldehydes/ketones: a green route to the racemic clopidogrel
-
An electrocatalytic reductive amination of electron-deficient aldehydes/ketones was developed, which could be used in the synthesis of functionalized tertiary amines and large scale preparation of racemic clopidogrel. A plausible mechanism involving an iminium cation intermediate was proposed.
- Zhang, Qianyun,Zhu, Wen,Yao, Jinzhong,Zhou, Hongwei,Li, Xiaofang
-
supporting information
p. 8462 - 8466
(2018/12/13)
-
- A five coordination Cu(II) cluster-based MOF and its application in the synthesis of pharmaceuticals: Via sp3 C-H/N-H oxidative coupling
-
Herein, a copper metal-organic framework, termed as VNU-18, containing penta-coordinated sites was successfully synthesized and fully characterized. This material was demonstrated to be an efficient heterogeneous catalyst for the oxidative C-H activation via N-H bonds. The optimized conditions are applicable for the synthesis of pharmaceuticals constructed by α-amino carbonyl skeletons.
- Tran, Thuan V.,Le, Hanh T. N.,Ha, Hiep Q.,Duong, Xuan N. T.,Nguyen, Linh H.-T.,Doan, Tan L. H.,Nguyen, Ha L.,Truong, Thanh
-
p. 3453 - 3458
(2017/08/22)
-
- Enantioselective Palladium-Catalyzed Carbene Insertion into the N?H Bonds of Aromatic Heterocycles
-
C3-substituted indoles and carbazoles react with α-aryl-α-diazoesters under palladium catalysis to form α-(N-indolyl)-α-arylesters and α-(N-carbazolyl)-α-arylesters. The products result from insertion of a palladium-carbene ligand into the N?H bond of the aromatic N-heterocycles. Enantioselection was achieved using a chiral bis(oxazoline) ligand, in many cases with high enantioselectivity (up to 99 % ee). The method was applied to synthesize the core of a bioactive carbazole derivative in a concise manner.
- Arredondo, Vanessa,Hiew, Stanley C.,Gutman, Eugene S.,Premachandra, Ilandari Dewage Udara Anulal,Van Vranken, David L.
-
p. 4156 - 4159
(2017/04/03)
-
- Formamides as Lewis Base Catalysts in SNReactions—Efficient Transformation of Alcohols into Chlorides, Amines, and Ethers
-
A simple formamide catalyst facilitates the efficient transformation of alcohols into alkyl chlorides with benzoyl chloride as the sole reagent. These nucleophilic substitutions proceed through iminium-activated alcohols as intermediates. The novel method, which can be even performed under solvent-free conditions, is distinguished by an excellent functional group tolerance, scalability (>100 g) and waste-balance (E-factor down to 2). Chiral substrates are converted with excellent levels of stereochemical inversion (99 %→≥95 % ee). In a practical one-pot procedure, the primary formed chlorides can be further transformed into amines, azides, ethers, sulfides, and nitriles. The value of the method was demonstrated in straightforward syntheses of the drugs rac-Clopidogrel and S-Fendiline.
- Huy, Peter H.,Motsch, Sebastian,Kappler, Sarah M.
-
p. 10145 - 10149
(2016/08/16)
-
- METHOD OF CONVERTING ALCOHOL TO HALIDE
-
The present invention relates to a method of converting an alcohol into a corresponding halide. This method comprises reacting the alcohol with an optionally substituted aromatic carboxylic acid halide in presence of an N-substituted formamide to replace a hydroxyl group of the alcohol by a halogen atom. The present invention also relates to a method of converting an alcohol into a corresponding substitution product. The second method comprises: (a) performing the method of the invention of converting an alcohol into the corresponding halide; and (b) reacting the corresponding halide with a nucleophile to convert the halide into the nucleophilic substitution product.
- -
-
-
- Concise Synthesis of (±)-Clopidogrel via Carboxylation of Benzylamine with CO2
-
A concise and efficient synthesis of (±)-clopidogrel, an antithrombotic agent, is achieved by inserting CO2 at the benzylic position as the key reaction without using any toxic transition metals. The overall yield of the synthetic process is 38% and the salient features include operationally simple process chemistry and fewer steps.
- Venkataramasubramanian,Sudalai, Arumugam
-
p. 2099 - 2105
(2015/09/01)
-
- Prodrugs of anti-platelet agents
-
The invention relates to the compounds of formula I, formula II, formula Ia, formula IIb or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula Ia, formula IIb and methods for treating or preventing atherothrombosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.
- -
-
-
- Simple catalytic mechanism for the direct coupling of α-carbonyls with functionalized amines: A one-step synthesis of plavix
-
The direct α-amination of ketones, esters, and aldehydes has been accomplished via copper catalysis. In the presence of catalytic copper(II) bromide, a diverse range of carbonyl and amine substrates undergo fragment coupling to produce synthetically useful α-amino-substituted motifs. The transformation is proposed to proceed via a catalytically generated α-bromo carbonyl species; nucleophilic displacement of the bromide by the amine then delivers the α-amino carbonyl adduct while the catalyst is reconstituted. The practical value of this transformation is highlighted through one-step syntheses of two high-profile pharmaceutical agents, Plavix and amfepramone.
- Evans, Ryan W.,Zbieg, Jason R.,Zhu, Shaolin,Li, Wei,Macmillan, David W. C.
-
supporting information
p. 16074 - 16077
(2013/11/19)
-
- COMPOSITIONS AND METHODS FOR THE TREATMENT OF ATHEROTHROMBOSIS
-
The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for peroral administration- transdermal administration, transmucosal, syrups, topical, extended release, sustained release, or injection. Such compositions may foe used to treatment of vascular disorders or conditions such as thrombotic cerebrovascular or cardiovascular disease or its associated complications.
- -
-
-
- PRODRUGS OF ANTI-PLATELET AGENTS
-
Disclosed is the compounds of formula (I), formula (II), formula (la), formula (IIb) or its pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising and effective amount of formula (I), formula (II), formula (la), formula (lIb) and may be used to treatment or management of ischemia, stroke, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovasculard diseases and blood colts.
- -
-
-
- COMPOSITIONS AND METHODS FOR TREATING ATHEROTHROMBOSIS
-
Provided are compounds of formula (I), pharmaceutical acceptable salts, polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising the compounds may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup or injection, and may be used for the treatment or management of ischemia, cerebral thrombosis, arterial thrombosis, thrombotic cerebrovascular, cardiovascular diseases and blood clots.
- -
-
-
- DRUG DERIVATIVES
-
The present invention relates to derivatives of known active pharmaceutical compounds. These derivatives are differentiated from the parent active compound by virtue of being redox derivatives of the active compound. This means that one or more of the functional groups in the active compound has been converted to another group in one or more reactions which may be considered to represent a change of oxidation state. We refer to these compounds generally as redox derivatives. The derivatives of the invention may be related to the original parent active pharmaceutical compound by only a single step transformation, or may be related via several synthetic steps including one or more changes of oxidation state. In certain cases, the functional group obtained after two or more transformations may be in the same oxidation state as the parent active compound (and we include these compounds in our definition of redox derivatives). In other cases, the oxidation state of the derivative of the invention may be regarded as being different from that of the parent compound. In many cases, the compounds of the invention have inherent therapeutic activity on their own account. In some cases, this activity relative to the same target or targets of the parent compound is as good as or better than the activity which the parent compound has against the target or targets.
- -
-
Paragraph 0291; 0292
(2013/09/12)
-
- METHOD FOR MANUFACTURING CRYSTALLINE FORM (I) OF CLOPIDOGREL HYDROGEN SULPHATE
-
The present invention provides a method for manufacturing a crystalline form (I) of clopidogrel hydrogen sulphate(clopidogrel hydrogen sulfate), including reacting a clopidogrel free base with concentrated sulfuric acid in the presence of a mixed solvent containing water in an amount of 4 to 14% by weight based on the weight of the clopidogrel free base and 2-butanol.
- -
-
Page/Page column 6-7
(2011/08/03)
-
- 2-Chlorophenyl zinc bromide: A convenient nucleophile for the mannich-related multicomponent synthesis of clopidogrel and ticlopidine
-
A methodological study devoted to the Mannich-like multicomponent synthesis of the antiplatelet agent (±)-clopidogrel (7) and the ethyl ester analogue 6 is described. The process involves the formation of 2-chlorophenyl zinc bromide (2) and its subsequent reaction with an alkyl glyoxylate and 4,5,6,7-tetrahydrothieno[3,2-c]pyridine (3). We demonstrate that the organozinc reagent 2 also constitutes a very convenient nucleophile for the multicomponent synthesis of the benzylamine core of ticlopidine (9).
- Isabelle, Aillaud,Haurena, Caroline,Gall, Erwan Le,Martens, Thierry,Ricci, Gino
-
experimental part
p. 8144 - 8155
(2011/02/27)
-
- PROCESS FOR THE PREPARATION OF CLOPIDOGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
-
The present invention provides a process for the preparation of clopidogrel and its pharmaceutically acceptable salts thereof comprises the resolving racemic methyl alpha-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl)(2-chlorophenyl)-acetate by the salt formation of methyl alpha-5-(4,5,6,7-tetrahydro[3,2-c]thienopyridyl)(2-chlorophenyl)-acetate with excess levorotatory camphor-10-sulfonic acid to get a maximum yield of camphor sulphonate salt of methyl S-(+)-alpha-5-(4,5,6,7-tetrahydro[3,2-e]thienopyridyl)(2-chlorophenyl)-acetate and transforming the camphor sulphonate salt to clopidogrel or its pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 3
(2010/02/17)
-
- A PROCESS FOR THE PREPARATION OF S-CLOPIDOGREL
-
A process for the preparation of (S) - Clopidogrel free base or a pharmaceutically acceptable salt thereof by the racemization of the undesired (R) - Clopidogrel in the presence of a suitable base followed by resolution with camphor sulfonate salt and further treatment with an inorganic acid to yield the title compound.
- -
-
Page/Page column 10-11
(2010/05/13)
-
- Processes for the preparation of clopidogrel
-
The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(?) clopidogrel. The process includes the step of reacting R(?) clopidogrel with a powered anhydrous base in one or more solvents.
- -
-
Page/Page column 3
(2010/06/14)
-
- RACEMIZATION PROCESS FOR THE PREPARATION OF AN INTERMEDIATE OF CLOPIDOGREL HYDROGEN SULPHATE
-
The invention relates to a process for the preparation of the pharmaceutically applicable methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate hydrogen sulphate (also known as S-(+)-clopidogrel hydrogen sulphate) of formula (I) comprising racemizing methyl (R)-(-)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine- 5(4H)-acetate or methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)- acetate, or a mixture thereof in any proportion with a weak base in the presence of an organic solvent, converting the methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno [3,2-c]pyridine-5(4H)-acetate of fomula (II) obtained to its sulphuric acid addition salt methyl (R,S)-(±)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulphate and converting it to methyl (S)-(+)-α-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c] pyridine-5(4H)-acetate hydrogen sulphate of formula (I) by known manner.
- -
-
Page/Page column 11
(2009/07/18)
-
- PROCESS FOR THE PREPARATION OF POLYMORPHIC FORMS OF CLOPIDOGREL HYDROGEN SULFATE
-
The present invention relates to a novel process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate, namely methyl(+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate hydrogen sulfate of formula (I). Particularly the present invention relates to the process for the preparation of form (I) and amorphous clopidogrel hydrogen sulfate.
- -
-
Page/Page column 5-6
(2009/04/24)
-
- Multicomponent reactions as a powerful tool for generic drug synthesis
-
Multicomponent reactions (MCRs) are not only a powerful tool for drug discovery, they also represent an excellent methodology for synthesis rationalization. Here we wish to illustrate the potential of MCRs in the production of generic drugs by synthesizing, in racemic form, the antiplatelet agent clopidogrel and the nonsteroidal antiandrogen bicalutamide, using Ugi, Petasis and Passerini reactions. Georg Thieme Verlag Stuttgart.
- Kalinski, Cedric,Lemoine, Hugues,Schmidt, Juergen,Burdack, Christoph,Kolb, Juergen,Umkehrer, Michael,Ross, Guenther
-
scheme or table
p. 4007 - 4011
(2009/05/27)
-
- Process for preparing clopidogrel
-
The present invention encompasses processes for the preparation of optically pure clopidogrel camphorsulfonic acid salt without the need to isolate or recover (±) clopidogrel.
- -
-
Page/Page column 6-7
(2008/12/09)
-
- Preparation of Clopidogrel and Its Analogues Methyl Tetrahydrothienopyridine Acetate Compuunds
-
The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.
- -
-
Page/Page column 11
(2008/12/08)
-
- PREPARATION OF CLOPIDOGREL AND ITS ANALOGUES METHYL TETRAHYDROTHIENOPYRIDINE ACETATE COMPOUNDS
-
The present invention disclosed a preparation method of Clopidogrel (X=2-Cl) and its analogues of methyl tetrahydrothienopyridine acetate (I) by using halogen phenyl acetonitrile (VIII) as starting material and tetrahydrothienopyridine acetonitrile (IV), tetrahydrothienopyridine acetate (V) as key intermediates, and further using kinetic resolution to prepare the optical active Clopidogrel and compounds of methyl tetrahydrothenopridine acetate of formula (XII). The Clopidogrel of present invention is a novel high effective and safety drug for inhibition of platelet aggregation. This invention applied systematic technique of racemization of unwanted optical active enantiomer, recover recycle and reuse of resolution agent etc., with greater economic advantages and suitable for commercial scale industrial production. Wherein: X represents atoms of hydrogen, fluorine, chlorine, bromine or iodine, M represents an alkali metal ion.
- -
-
Page/Page column 15; 16; 17; 22
(2008/12/06)
-
- Procedure for the preparation of methyl (+)-(S)-Alpha-(O-chlorophenyl)-6,7-dihydrothieno-[3,2-C]pyridine-5(4H) acetate
-
A process for the preparation of Methyl (+)-(S)-α-(o-chlorophenyl)-6,7-dihydrothieno-[3,2-c]pyridine-5(4H)acetate of formula I: the process comprising: a. reacting 4,5,6,7-tetrahydro[3,2-c]thieno pyridyl methane (II) with 2-halophenyl acetic acid derivative of formula III b. extracting the formed product (+/-) clopidogrel in to solvent from the reaction mixture of step a; c. resolution of (+/-) clopidogrel of step b with levorotatory camphor sulfonic acid and isolation of the (+) clopidogrel camphor sulfonic acid salt; d. purifying (+) clopidogrel camphor salt; and e. neutralization of the camphor salt of step d with aqueous base in solvent and isolation of (+) clopidogrel base by separation and removal solvent.
- -
-
Page/Page column 9
(2008/12/04)
-
- PROCESSES FOR THE PREPARATION OF CLOPIDOGREL
-
The invention relates to processes for the preparation of clopidogrel and salts thereof. The inventors have developed a process for preparing racemic clopidogrel by racemizing R(-) clopidogrel. The process includes the step of reacting R(-) clopidogrel with a powered anhydrous base in one or more solvents.
- -
-
Page/Page column 5; 6
(2009/01/20)
-
- PROCESS FOR THE SYNTHESIS OF CLOPIDOGREL AND NEW FORMS OF PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF
-
The present invention relates to a new process for the preparation of clopidogrel and to new polymorphic forms of clopidogrel salts, to processes for their preparation and to a pharmaceutical formulation containing the new forms.
- -
-
Page/Page column 37
(2008/06/13)
-
- Synthetic improvements in the preparation of clopidogrel
-
Synthetic improvements in the preparation of clopidogrel are described. The synthesis was accomplished in four steps or one-pot in above 70% overall yield. The process featured PTC catalyzed alkaline hydrolysis of the key intermediate 2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetonitrile and highly effective kinetic resolution of racemic clopidogrel using L-camphorsulphonic acid in toluene and has been successfully used in a 50-kg pilot test.
- Wang, Lixin,Shen, Jianfen,Tang, Yi,Chen, Yi,Wang, Wen,Cai, Zegui,Du, Zhenjun
-
p. 487 - 489
(2012/12/31)
-
- PROCESS FOR THE PREPARATION OF POLYMORPHIC FORMS OF CLOPIDOGREL HYDROGEN SULFATE
-
The present invention relates to a novel process for the preparation of polymorphic forms of clopidogrel hydrogen sulfate, namely methyl (+)-(S)-α-(o-chlorophenyl)-6,7-dihydrotliieno [3,2-c] pyridine-5(4H)-acetate hydrogen sulfate of formula (I). Particularly the present invention relates to the process for the preparation of form (I) and amorphous clopidogrel hydrogen sulfate.
- -
-
Page/Page column 14-15
(2008/06/13)
-
- Industrial process for preparation a polmorph of clopidogrel hydrogen sulphate
-
An improved process for the manufacture of Clopidogrel starting from 2-(2-thienyl) ethylamine, which eliminates the isolation of an unstable intermediate like 2-(2-thienyl) ethyl formimine by subjecting it to a one pot cyclization to get 4,5,6,7-tetrahydrothieno (3,2-c) pyridine of Formula II and further reacting with halo-compound of Formula III (where X is Cl or Br) at 20 to 90 °C temperature characterized in a solvent like water and/or dichloroethane in presence of organic or inorganic bases is disclosed herein. This invention further discloses a process for resolution of racemic clopidogrel into its optical antipodes and converting the dextroclopidogrel base into its known polymorphs namely 'Form I' or 'Form II' in solvents selected from methyl propyl ketone, methyl isopropyl ketone, diethyl ketone or their mixture thereof, mixture of ethyl acetate and methyl propyl ketone, mixture of ethyl acetate and methyl isopropyl ketone, or mixture of ethyl acetate and diethyl ketone or ethyl acetate.
- -
-
Page/Page column 10
(2008/06/13)
-
- METHOD OF OBTAINING CLOPIDOGREL
-
Separation of the camphorsulfonic salts of the compounds of formula (I) and (II) by one or more crystallizations from a mixture of two solvents, both R(-)-10-camphorsulfonic acid and its salts with the compounds of formula (I) and (II) being well soluble in at least one of the components, the formula of which can be indicated as RaOH, wherein Ra is a straight or branched C1 to C5 alkyl. In the other components, camphorsulfonic acid and its salts are less soluble; however, they dissolve compounds of formula (I) and (II) very well.
- -
-
Page/Page column 11
(2008/06/13)
-
- METHOD OF RACEMIZATION OF THE R(-) ISOMER OF THE (2-CHLOROPHENYL)-6,7- DIHYDROTHIENO[3,2-c]PYRIDINE-5(4H)-ACETIC ACID METHYL ESTER
-
Racemization of the R(-) isomer of the (2-chlorophenyl) -6, 7-dihydrothieno [3, 2-c]pyridine- 5 (4H) -acetic acid methyl ester (Formula II) (also called R clopidogrel) is performed via conversion of a portion thereof to the S (+) isomer and it takes place
- -
-
Page/Page column 7-8
(2008/06/13)
-
- Process for the recovery of S -(+)-methyl- (2-chlorophenyl)- (6,7-dihydro- 4H-thieno [3,2-c] pyrid-5-yl) acetate hydrogen sulfate (clopidogrel bisulfate) from its (R) and mixture of (R) and (S)- isomers
-
A process for the recovery of compound of formula (I) where X represents hydrogen, fluoro, chloro, bromo or iodo atom, preferably 2-chloro which comprising the steps of f. preparing compound (?) or (±)-(2-chloro phenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate methyl ester hydrogen sulfate from its corresponding camphorsulfonic acid salt compound. g. transforming the obtained compound of step (a), into the compound of (2-chlorophenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetic acid. h. converting the compound of step (b) into racemic compound (±)-(2-chloro phenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate methyl ester hydrogen sulfate. i. resolving the obtained racemic compound of step (c), into the optically active (+)-(2-chloro phenyl)-(6,7-dihydro-4H-thieno[3,2-c]pyrid-5-yl)acetate methyl ester camphor sulfonic acid salt. j. further transforming the optically active (+) form compound of step (d) into their pharmaceutically acceptable salts.
- -
-
Page/Page column 4
(2008/06/13)
-
- Resolution of racemates of methyl alpha-5-[4,5,6,7-tetrahydro[3,2-C]thienopyridyl]-(2-chlorophenyl) acetate
-
A process for the resolution of each of the enantiomers of methyl-α-5-[4,5,6,7-tetrahydro[3,2-c]thienopyridyl]-(2-chlorophenyl)acetate and salts thereof by diastereomeric crystallization comprising the use of a single optically active resolving agent and
- -
-
Page/Page column 6
(2008/06/13)
-
- PROCESS FOR PREPARATION OF CLOPIDOGREL, ITS SALTS AND PHARMACEUTICAL COMPOSITIONS
-
The invention discloses an improved process for racemization of methyl (R)-(-) alpha-(2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetate , a stereoisomer formed in the synthesis of clopidogrel i.e. methyl (S)-(+)-alpha- (2-chlorophenyl)-6,7-dihydro-thieno[3,2-c]pyridine-5(4H)-acetate or its salts. The invention is also for an improved process for production of clopidogrel or its pharmaceutically acceptable salts. The invention further discloses novel clopidogrel salts and pharmaceutical compositions comprising them.
- -
-
-
- RACEMIZATION AND ENANTIOMER SEPARATION OF CLOPIDOGREL
-
Processes for separation of enantiomers of clopidogrel, and converting one enantiomer of clopidogrel to another enantiomer of clopidogrel are provided. The enantiomers are separated by crystallizing the (S) enantiomer as camphor sulfonate salt from a hydrocarbon, or a mixture of a hydrocarbon and a co-solvent, preferably DMF:toluene. The (R) enantiomer is then racemized and recycled by reaction with a catalytic amount of a base, preferably with t-butoxide.
- -
-
-
- MEDICINAL COMPOSITIONS
-
The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug and provides good sensation upon oral administration, and therefore is easily ingested by even the elderly, children, and patients suffering dysphagia. Moreover, the product is suitable for administration using tube.
- -
-
-
- Process for the preparation of a pharmacologically active substance
-
The present invention relates to a process for the preparation of the racemic or optically active compounds of general formula (VI): wherein the meaning of X is a halogen atom, or their salts, characterized in that, a racemic or optically active new compound of general formula (VII): wherein the meaning of X is a halogen atom, is transformed into the racemic or optically active compound of general formula (VIII):
- -
-
-
- Intermediates and process for the preparation thereof
-
A process for the preparation of [2-(2-thienyl)-ethylamino]-(2-halogenophenyl)-acetonitriles of general formula (I) starting from 2-(2-thienyl)-ethyl-amine, alkalicyanide and o-halogeno-benzaldehyde. Compounds of general formula (I) are valuable intermediates.
- -
-
-
- THIENO [3,2-c] PYRIDINE DERIVATIVES AND THEIR THERAPEUTIC APPLICATION
-
This invention relates to new thieno [3,2-c] pyridine derivatives having the formula: (I) in which: Y represents the OH group or an OR group in which R is a straight or branched lower alkyl radical, or Y represents a group in which R1 and R2 are each inde
- -
-
-